Ventricular Assist Devices Market - Regional Analysis
North America Market Insights
The ventricular assist devices market in North America is anticipated to garner a maximum share of 45.5% by 2037, owing to the presence of advanced healthcare infrastructure and a high rate of heart failure cases. The FDA approvals are becoming fast-tracked, enabling faster commercialization. Prominent hospitals such as the Mayo and Cleveland Clinic have reported a 21% annual surge in VAD implants. Manufacturers in the region are addressing these hurdles by making strategic partnerships and introducing various training initiatives. Also, there is an increasing investment in AI-enabled remote monitoring, which is also fueling the ventricular assist devices market growth in the region.
The market in the U.S. is driven by humongous federal investments and the presence of favorable reimbursement policies. The National Coverage Determination policy was revised in 2020, permitting the local MACs to give VAD implantation approval. Additionally, the spending from Medicare on VADs has reached USD 805 million, showcasing a 15.4% surge from the last 4 years. The Centers for Disease Control and Prevention found that heart failure is affecting over 6.51 million residents, directly supporting the demand for the VAD in the country.
Asia-Pacific Market Insights
The Asia Pacific ventricular assist devices market is anticipated to garner a CAGR of 12.8% during the forecasted period, owing to aging demographics and a surge in healthcare funding. Japan and China are the leading countries and dominate the market in the region due to the presence of advanced healthcare infrastructure. In Japan, the government's spending on cardiac infrastructure was 12.2% higher in 2024 in comparison with 2022. Also, in 2024, there were almost 45,100 VAD recipients in the country. In 2023, the Tokyo University Hospital implanted almost 510 HeartMate 3 devices.
Ventricular Assist Devices Market – Country-wise Overview
|
Country |
Government Investment & Trends |
Recent Industry Developments |
|
China |
Govt spending on cardiovascular devices ↑15.2% (2018–2023); over 1.5M HF patients diagnosed in 2023 |
NMPA approved 4th domestic LVAD (2023); local players like Suzhou Evaheart are expanding production |
|
India |
Spending ↑18.1% (2015–2023); $1.8B annually; >2.4M patients treated in 2023 |
HeartMate 3 & Jarvik 2000 imported |
|
Indonesia |
Public cardiac care funding ↑12.2% since 2020; VAD access via BPJS (universal healthcare) is increasing |
Jakarta Heart Institute partnered with Medtronic for training and VAD deployment (2024) |
|
Malaysia |
VAD patient volume doubled (2013–2023); 21% rise in gov’t funding over decade |
National Heart Institute (IJN) expanded implantable VAD program; Abbott partnered on training |
|
Australia |
Medicare supports advanced cardiac devices; >2,000 VAD implants annually |
HeartWare HVAD and HeartMate 3 are widely used |
|
South Korea |
Estimated ₩260B allocated; ~20,000 implantations reported in 2022 |
Seoul National University Hospital collaborates with Abiomed; VAD trials funded by the MOHW |
